论文部分内容阅读
目的 :对头孢唑林钠和头孢哌酮钠治疗社区获得性肺炎 (CAP)进行经济学分析 ,为临床提供最佳治疗方案。方法 :采用随机分组对照进行临床试验观察 ,分析头孢唑林钠和头孢哌酮钠治疗成本和效果。结果 :头孢唑林钠和头孢哌酮钠治疗CAP有效率分别为 83.3%和 87.5 %,效果无显著性差异 (P >0 .0 5 ) ;治疗成本分别为 96 8.2 0元和 12 4 9.0 0元 ,有显著性差异。结论 :头孢唑林钠治疗CAP较头孢哌酮钠经济 ,更符合药物经济学原则
OBJECTIVE: To conduct an economic analysis of cefazolin sodium and cefoperazone sodium in the treatment of community-acquired pneumonia (CAP), providing the best treatment for clinical practice. Methods: A randomized controlled clinical trial was conducted to evaluate the cost and effectiveness of cefazolin sodium and cefoperazone sodium. Results: The effective rates of cefazolin sodium and cefoperazone sodium in treatment of CAP were 83.3% and 87.5%, respectively, with no significant difference in effect (P> 0.05); the treatment costs were 96.82 yuan and 124.090 yuan respectively, with Significant difference. Conclusion: Cefazolin sodium treatment of CAP than cefoperazone sodium economy, more in line with the principles of drug economics